Search Results
Your search for ,kEY matches 7151 pages
Showing 101 - 150Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal Cancers Symposium. Of 41 evaluable patients treated with single-agent...
PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50%
A PSMA-11 PET/CT scan with gallium Ga-68 led to the identification of more aggressive prostate cancer cells in men with equivocal or nonsuspicious findings on multiparametric MRI than a standard biopsy, according to first results from the phase III PRIMARY2 trial presented at the 2026 Annual...
Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer
As reported in JAMA Oncology by Yang et al, the 3-year follow-up of the predominantly Chinese phase III RATIONALE-309 trial showed a maintained progression-free survival benefit with the addition of first-line tislelizumab to chemotherapy in patients with recurrent or metastatic nasopharyngeal...
Women More Likely to Survive Cancer—But Suffer More Severe Side Effects
Women are more likely to survive cancer than men, but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study. Published by Chhetri et al in the Journal of the National Cancer Institute, the research identified consistent differences...
Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers
Romiplostim was beneficial in treating chemotherapy-induced thrombocytopenia, according to findings from the global phase III RECITE trial published in The New England Journal of Medicine. “This work has been nearly a decade in the making, and it is so important because there are no available...
New Prostate Cancer Risk Classification With PSMA-PET
In a study reported in The Lancet Oncology, Karpinski et al developed a new prostate cancer risk classification using PSMA-PET Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP) nomograms (PPP3) to provide prognostic values for overall survival at 3, 5, and 7 years. Study...
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
In a Chinese phase III trial (CAMPASS) reported in The Lancet Oncology, Zhong et al found that the PD-L1 inhibitor benmelstobart plus the tyrosine kinase inhibitor anlotinib significantly improved progression-free survival vs placebo plus pembrolizumab in the first-line treatment of PD-L1–positive...
Neha Vapiwala, MD, on Highlights in Prostate Cancer From ASCO GU 2026
Neha Vapiwala, MD, of the University of Pennsylvania, discusses key themes in prostate cancer data presented at this year’s symposium, including personalization of therapy, treatment sequencing considerations, the role of radiopharmaceuticals, long-term radiotherapy results, using AI and associated ...
No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma
Recurrence-free survival was similar between adjuvant therapy with the PD-1 inhibitor pembrolizumab and placebo in patients with hepatocellular carcinoma who achieved a complete radiologic response after surgical resection or local ablation, based on the phase III KEYNOTE-937 trial.1 Presented at...
p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors
In a phase I trial (PYNNACLE) reported in The New England Journal of Medicine, Dumbrava et al described the toxicity and preliminary activity of rezatapopt in TP53 Y220C–mutated solid tumors. The agent is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to ...
BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma
In a Chinese phase II study (CAREMM-001) reported in the Journal of Clinical Oncology, Yan et al found that B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was highly active in patients with newly diagnosed multiple myeloma who were ineligible for or did not proceed...
Disease Stage at Breast Cancer Diagnosis Impacted by Region, Race, and Insurance
Significant differences were found in advanced-stage diagnoses of breast cancer in rural populations according to geographic location in the United States, which were further influenced by demographic factors of race and insurance status, according to findings from an analysis of the National...
Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy
A structured exercise program in patients with cancer receiving chemotherapy led to a reduction in self-reported cognitive impairment vs those receiving chemotherapy who were not on an exercise plan, according to findings from a nationwide, randomized phase III trial published in JNCCN—Journal of...
Metastatic Uveal Melanoma: Nivolumab/Ipilimumab Plus Percutaneous Hepatic Perfusion
In a Dutch single-center phase II trial (CHOPIN) reported in The Lancet Oncology, van den Hoek et al found that the addition of nivolumab and ipilimumab to percutaneous hepatic perfusion improved progression-free survival in patients with metastatic uveal melanoma. Study Details Seventy-six...
AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden
Integration of artificial intelligence (AI) into screening workflows increased the detection of breast cancer by 10.4% in the United Kingdom, according to the results of the GEMINI study published in Nature Cancer. Additionally, use of AI in different workflows led to reductions in workload by up...
Recipients Named for the 2026 Pezcoller Foundation–AACR International Award
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas R. Lowy, MD, and John T. Schiller, PhD, during the AACR Annual Meeting 2026, in San Diego. Drs. Lowy and Schiller Dr. Lowy is...
Prostate Cancer: Low Testosterone Levels May Be Associated With Increased Risk of Progression During Surveillance
A new study has found that patients with prostate cancer and low testosterone levels may have a higher risk of their cancer progressing to a more aggressive form while under active surveillance. The findings, published by Lawen et al in the The Journal of Urology, suggest that baseline testosterone ...
Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer
In an Italian single-center phase II trial (SURE-02) reported in The Lancet Oncology, Necchi et al found that neoadjuvant sacituzumab govitecan-hziy plus perioperative pembrolizumab produced a “promising” clinical complete response rate in patients with muscle-invasive bladder cancer who were...
Addition of Axitinib to Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors
In a European phase II/III trial (AXINET) reported in the Journal of Clinical Oncology, Garcia-Carbonero et al found that the addition of axitinib to long-acting octreotide appeared to show activity in patients with advanced extrapancreatic neuroendocrine tumors (epNETs). Study Details The...
AI-Backed Liquid Biopsies Identify Liver Diseases
Building upon the foundation of liquid biopsy utility for the early detection of cancer, analysis of genome-wide cell-free DNA fragmentation with machine learning classification and modeling can also extend to the identification of liver cirrhosis and other chronic diseases, according to findings...
TACE With Camrelizumab and Rivoceranib in Unresectable Hepatocellular Carcinoma
In a Chinese phase II trial (CHANCE2005/CARES-005) reported in the Journal of Clinical Oncology, Zhu et al found that the addition of camrelizumab and rivoceranib to transarterial chemoembolization (TACE) improved progression-free survival in patients with unresectable hepatocellular carcinoma....
Cumulative Incidence of Advanced Breast Cancer in Japanese Women Aged 40 to 49 Years With Addition of Ultrasonography to Mammography Screening
As reported in The Lancet by Harada-Shoji et al, the Japanese J-START trial showed that adjunctive ultrasonography was associated with a reduced cumulative incidence of advanced breast cancer vs mammography alone in screening of asymptomatic women aged 40 to 49 years. Initial reports from the trial ...
HPV Vaccination Protection From Cervical Cancer Sustained Long Term
Quadrivalent human papillomavirus (HPV) vaccination led to a significantly reduced risk of invasive cervical cancer that was sustained through long-term follow-up, according to the results of a Swedish nationwide, register-based cohort study published in The BMJ. “This study provides evidence of...
Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma
As reported in the Journal of Clinical Oncology by Scherpereel et al, 5-year findings from the phase III CheckMate 743 trial showed continued overall survival benefit of first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectable pleural mesothelioma. Study Details In the...
FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma
On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a...
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.1 Of 41 evaluable patients treated with...
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence
Short-term exposure to low-dose vaginal estrogen therapy may relieve some symptoms of menopause for younger survivors of endometrial cancer without increasing the risk of endometrial cancer recurrence, according to findings from a study published in Menopause. “Early detection and improved,...
Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis
In a retrospective study reported in The Lancet Oncology, Lalchungnunga et al tested the classification accuracy of a molecular inference–based artificial intelligence (AI) model (Neuropath-AI) in central nervous system (CNS) tumor diagnosis. Study Details The multi-institutional study included...
Social Cue Prompts Reduce Sharing of Cancer Treatment Misinformation
Prompts on posts with social cues—such as messages indicating how many users have flagged a post—and clear platform review policies may encourage intervention and reduce sharing of cancer treatment misinformation on social media, according to Lazard et al, who reported findings from their online...
Colorectal Cancer: ACS Report Shows Increasing Incidence, Mortality Rates in Younger Adults
Findings from the American Cancer Society's triennial report, Colorectal Cancer Statistics, 2026, show that rates of colorectal cancer are decreasing in older adults; however, rates of colorectal cancer incidence in younger adults continue to increase, with a greater proportion of these cancers...
Research Suggests AI Pathology Models May Take Unreliable 'Shortcuts' to Identify Cancer Biomarkers
Artificial intelligence (AI) tools that detect molecular biomarker status from histologic images may be dependent upon correlational relationships with clinicopathologic features, preventing the models from learning the true causal effect of the biomarker, according to findings published in Nature...
Lisocabtagene Maraleucel in Relapsed or Refractory MZL
In a phase II trial (TRANSCEND FL) reported in The Lancet, Palomba et al found that the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel was active in patients with relapsed or refractory marginal zone lymphoma (MZL). Study Details In the international multicenter trial, 67...
Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer
As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfortumab vedotin plus pembrolizumab to radical cystectomy in patients with muscle-invasive bladder...
Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
Combining a visual inspection of the bladder—systematic endoscopic evaluation—with a blood test to check for the presence of circulating tumor DNA (ctDNA) may accurately predict which patients with bladder cancer still have cancer in their bladder after treatment and which do not. These findings,...
Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
In an individual patient data meta-analysis reported at the 2026 ASCO Genitourinary Cancers Symposium (Abstract 305) and simultaneously published in The Lancet, Kishan et al found no apparent overall survival benefit of adding hormone therapy in patients undergoing postoperative radiotherapy after...
AI Model May Predict Cancer Risk in Patients With Colitis-Associated Low-Grade Dysplasia
In a new study published in Clinical Gastroenterology and Hepatology, Johnson et al reported that an automated artificial intelligence (AI) pipeline using large language models (LLMs) can accurately stratify future risk of advanced neoplasia in patients with colitis-associated low-grade dysplasia....
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?
Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approach, according to findings from the RETAIN trials presented at the 2026 ASCO Genitourinary Cancers...
Advanced RCC: After Immunotherapy, Belzutifan Plus Lenvatinib or Cabozantinib?
At the 2026 ASCO Genitourinary Cancers Symposium, Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, presented results from the second interim analysis of the phase III LITESPARK-011 trial showing improved progression-free survival, higher objective response rate, and a trend toward...
Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions
Skin fluorescent imaging showed high sensitivity and specificity for the discrimination of low- and high-risk lesions, demonstrating an alternative, noninvasive approach to melanoma biopsies, according to findings from a phase II trial published in JAAD International. “By identifying the molecular ...
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer
The results from the randomized phase III KEYNOTE-B15/EV-304 study show that neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rate in patients with muscle-invasive bladder cancer who were...
Advanced Nonsquamous NSCLC: FDA Grants Accelerated Approval to Zongertinib
On February 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain ...
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsored by a pharmaceutical company with an interest in prostate cancer treatments, extolled the virtues ...
Nomogram for Metastasis-Directed SBRT in PSMA PET-Staged Oligorecurrent Prostate Cancer
In a European retrospective study (PORTAL) reported in The Lancet Oncology, Soeterik et al developed a nomogram for predicting androgen-deprivation therapy (ADT)–free survival with metastasis-directed stereotactic body radiotherapy (SBRT) in patients with prostate-specific membrane antigen (PSMA)...
Lung Cancer: Variability of Open-Source AI Models in EGFR Mutation Prediction
In a study reported in JAMA Oncology, Rakaee et al identified the accuracy of open-source artificial intelligence (AI) models in predicting the presence of EGFR mutations in samples from patients with lung adenocarcinoma, including according to ancestral subgroups. Study Details The study included...
Effect of Medicaid Expansion on Diagnosis, Treatment, and Outcomes in NSCLC
In a study reported in the Journal of Clinical Oncology, Zhao et al found that patients with non–small cell lung cancer (NSCLC) in Medicaid expansion states have had improvements in earlier diagnosis, early initiation of treatment, and survival. Study Details In the study, patients newly diagnosed...
Cancer Diagnoses During COVID-19 Pandemic: Impact on 1-Year Cause-Specific Survival
In a study reported in JAMA Oncology, Burus et al found that patients diagnosed with invasive cancer during 2020 and 2021—the first 2 years of the COVID-19 pandemic—had poorer 1-year cause-specific survival (CSS) rates vs patients diagnosed in the prepandemic years of 2015 to 2019. Study Details...
Long-Term Health Risks for Testicular Cancer Survivors Differ by Chemotherapy Regimen
Long-term effects on renal function, cardiovascular risk, and overall health burden in survivors of testicular cancer differed according to the chemotherapy regimen each patient received, according to the results of a large real-world study published in JNCCN—Journal of the National Comprehensive...
Introducing ASCO AI in Oncology
In February, ASCO and Conexiant launched ASCO AI in Oncology (ascoai.org), a digital platform dedicated to understanding how artificial intelligence (AI) is impacting cancer care. “Our goal with this hub is to empower oncology professionals with knowledge and the tools to adapt to a rapidly...
MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer
In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Louis et al found that magnetic resonance imaging (MRI)-guided optimization of duration of neoadjuvant chemotherapy was associated with favorable event-free survival in patients with stage II to III HER2-positive breast cancer....
ASCO’s First Living Guideline in GU Cancers Reflects Recent Practice-Changing Trials on Systemic Treatment of mCRPC
ASCO has published an updated guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), representing ASCO’s first Living Guideline in the area of prostate cancer and the first in any genitourinary (GU) cancer.1 “Guidelines will become less useful if...
